Industry news

Meeting Unmet Medical Needs: The Disparity Dilemma

By Kenneth I. Kaitin, PhD, Christopher-Paul Milne, DVM, MPH, JD / PharmExec.com

Although prescription drugs comprise a relatively small percentage of overall healthcare expenditures at 10%, they, nonetheless, represent the primary point-of-contact between the majority of the US population and the healthcare system; while 62% of Americans fill a prescription in any given year, only 8% typically experience a hospital stay. Thus, in an era of health reform, when a primary concern for decision-makers at all levels—policymakers, public health officials, practitioners—is how well our system is meeting the medical needs of the population, focusing on the role played by prescription drugs is essential.

Hot Health-Care Market Fuels Biggest VC-Backed IPO Wave Since 2000

Russ Garland / The World Street Journal

Venture capitalists enjoyed a strong exit market in 2014 with the most IPOs since 2000, led by the health-care sector.

India jumps into the generic drug biz to compete with commercial players on price

EJ Lane / Feirce Biotech

India's government is getting into the generic drug business. The state reportedly will launch its own brand, "Jan Aushadhi," on July 1, planning to sell up to 504 drugs on its "essential" list in direct competition with commercial drugmakers. The government drugs will be available only in Jan Aushadhi-branded hospital pharmacies, and hospitals may be required to use them.

Moody's: Big Pharmas face growing patent-loss threats, but some pipelines are improving

Tracy Staton / Fierce Pharma

For the past couple of years, the pharma industry has had something of a reprieve from patent-cliff nightmares. But according to Moody's Investors Service, some companies face new threats to their sweet dreams.

Technology that will change clinical research in the next 10 years

Douglas Bain / CEO at eClinicalHealth Limited

Social media, patient awareness & self assertion and Electronic Health data will all change how clinical research generally, and clinical trials specifically will be carried out over the next 10 years.

03 February 2015

Marinus Pharmaceuticals Initiates Clinical Trial with Ganaxolone in PCDH19 Female Pediatric Epilepsy

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, announced that it has initiated a Phase 2 clinical trial with ganaxolone, a synthetic analog of the endogenous neurosteroid allopregnanolone, in female children with epilepsy caused by a mutation of the protocadherin 19 gene (PCDH19). PCDH19 female pediatric epilepsy is a rare disease that is estimated to affect approximately 15,000-30,000 females in the U.S. and is characterized by onset of cluster seizures before age 5, cognitive and sensory impairment of varying degrees, and behavioral disturbances. 

Ebola Vaccine Trial Opens in Liberia

U.S. National Institute of Health

A large clinical trial to assess the safety and efficacy of two experimental vaccines to prevent Ebola virus infection is now open to volunteers in Liberia. The trial is being led by a recently formed Liberia-U.S. clinical research partnership and is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. 

Big Pharma farms out safety monitoring to $2B-and-growing industry

Tracy Staton / FiercePharma

Big Pharma has been hiring out all sorts of functions companies once did in-house: sales, manufacturing, and IT services, to name a few. But according toThe Wall Street Journal, one of the fastest-growing fields for pharma contractors isn't any of these. It's drug safety.

U.K. set to kick off huge genome project with U.S. right behind

Joseph Keenan / FierceMedicalDevices

A U.K. project designed to analyze up to 100,000 entire human genomes is set to begin tomorrow with a similar project in the U.S. focused on more than one million people expected to be announced later this week.

02 February 2015

NovaDigm Therapeutics, Inc. - Product Pipeline Review - 2014 - New Report Available

Global Markets Direct's, 'NovaDigm Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the NovaDigm Therapeutics, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of NovaDigm Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.